October 03, 2022
1 min watch
Save
VIDEO: Samsara Vision gives update on Sing IMT trial for late-stage AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Tom Ruggia, president and CEO of Samsara Vision, discusses the ongoing CONCERTO trial investigating the Sing IMT as well as the device’s commercialization around the world.
The trial is investigating the efficacy of the device on 100 patients with late-stage age-related macular degeneration with no history of cataract surgery.
Published by:
Sources/Disclosures
Collapse
Source:
Ruggia T. Technology/devices showcases. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Ruggia reports being the president and CEO of Samsara Vision.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.